Compare
Repligen Corp vs ADMA Biologics, Inc. vs Novavax Inc vs Bio-Techne Corp
| Latest fiscal year | Repligen Corp RGEN | ADMA Biologics, Inc. ADMA | Novavax Inc NVAX | Bio-Techne Corp TECH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $738.26M | $510.17M | $1.12B | $1.22B |
| Revenue growth (YoY) | +16.4% | +19.6% | +64.7% | -0.4% |
| Gross margin | 52.3% (computed) | 57.4% | 93.5% (computed) | 65.8% |
| Operating margin | 7.5% | 37.5% | 40.3% | 20.7% |
| Net margin | 6.6% | 28.8% | 39.2% | 15.0% |
| Net income | $48.89M | $146.93M | $440.30M | $181.86M |
| EPS (Diluted) | $0.86 | $0.60 | $2.58 | $1.16 |
| Operating cash flow | $117.42M | $50.40M | -$244.63M | $292.07M |
| Free cash flow | $93.90M | $27.82M | n/a | $263.22M |
| Cash & equivalents | $566.02M | $87.63M | $240.63M | $264.71M |
| Total assets | $2.95B | $624.24M | $1.18B | $2.59B |
| Total liabilities | $843.57M | $146.92M | $1.30B | n/a |
| Shareholders' equity | $2.11B | $477.32M | -$127.75M | $2.11B |
| Return on year-end equity | 2.3% | 30.8% | n/a | 8.6% |
| Shares outstanding | 56.33M | 237.87M | 162.58M | 156.10M |
Revenue, most recent five fiscal years
| Fiscal year | Repligen Corp | ADMA Biologics, Inc. | Novavax Inc | Bio-Techne Corp |
|---|---|---|---|---|
| Latest | $738.26M Ended 2025-12-31 | $510.17M Ended 2025-12-31 | $1.12B Ended 2025-12-31 | $1.22B Ended 2026-06-30 |
| 1 year earlier | $634.44M Ended 2024-12-31 | $426.45M Ended 2024-12-31 | $682.16M Ended 2024-12-31 | $1.22B Ended 2025-06-30 |
| 2 years earlier | $632.36M Ended 2023-12-31 | $258.21M Ended 2023-12-31 | $983.71M Ended 2023-12-31 | $1.16B Ended 2024-06-30 |
| 3 years earlier | $801.54M Ended 2022-12-31 | $154.08M Ended 2022-12-31 | $1.98B Ended 2022-12-31 | $1.14B Ended 2023-06-30 |
| 4 years earlier | $670.53M Ended 2021-12-31 | $80.94M Ended 2021-12-31 | $1.15B Ended 2021-12-31 | $1.11B Ended 2022-06-30 |